Plasma amyloid-beta peptides in acute cerebral ischemia: a pilot study

J Clin Lab Anal. 2012 Jul;26(4):238-45. doi: 10.1002/jcla.21511.

Abstract

Background: Blood-based tests for a rapid and valid diagnosis as well as outcome prognosis of acute stroke are desirable. Recently, plasma Aβ40 was suggested as an independent cerebrovascular risk factor candidate.

Methods: We investigated eight plasma samples of patients with clinical signs of acute cerebral ischemia for derangements of plasma amyloid-beta (Aβ) peptide patterns as compared to 13 patients with other neuropsychiatric diseases. For the analysis of plasma, we used immunoprecipitation followed by the quantitative Aβ-SDS-PAGE/immunoblot.

Results: The major outcome was a striking decrease of Aβ1-40 in plasma paralleled by an increase in the ratio of Aβ1-38/Aβ1-40 in two patients with acute stroke. Interestingly, these patients had an onset of symptoms within only 2-4 hr before venous puncture and there was a strong correlation of Aβ1-38/Aβ1-40 levels with the time span between onset of symptoms and venous puncture.

Conclusion: From these results, we suggest the ratio of plasma Aβ1-38/Aβ1-40 as a possible biomarker for the early diagnosis of acute stroke.

MeSH terms

  • Acute Disease
  • Amyloid beta-Peptides / blood*
  • Biomarkers / blood
  • Brain Ischemia / blood*
  • Electrophoresis, Polyacrylamide Gel
  • Humans
  • Immunoblotting
  • Immunoprecipitation
  • Middle Aged
  • Pilot Projects
  • Statistics, Nonparametric

Substances

  • Amyloid beta-Peptides
  • Biomarkers